Abbott Laboratories' stock has declined 30% over the past year but presents a buying opportunity for long-term investors due to its strong dividend program and potential for growth, particularly following its acquisition of Exact Sciences. The company aims to enhance sales through innovative products like its continuous glucose monitoring devices, making it an attractive option for those seeking quality dividend stocks.
Abbott Laboratories, currently down 30% from its peak, presents a potential investment opportunity for long-term dividend-focused investors. The company, a Dividend King with a 2.8% yield, is expanding its growth avenues through strategic acquisitions, such as Exact Sciences, and innovations in its continuous glucose monitoring devices. With the stock trading at historically low prices, it may offer attractive returns through dividend reinvestment and future growth.